117 related articles for article (PubMed ID: 8856492)
1. Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats.
Vidrio H; Sánchez-Salvatori MA; Medina M
J Cardiovasc Pharmacol; 1996 Aug; 28(2):332-6. PubMed ID: 8856492
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors.
Lake KD; Compton DR; Varga K; Martin BR; Kunos G
J Pharmacol Exp Ther; 1997 Jun; 281(3):1030-7. PubMed ID: 9190833
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
Wagner JA; Járai Z; Bátkai S; Kunos G
Eur J Pharmacol; 2001 Jul; 423(2-3):203-10. PubMed ID: 11448486
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of delta 9- and delta 9(11)-tetrahydrocannabinol and their interaction with epinephrine.
Estrada U; Brase DA; Martin BR; Dewey WL
Life Sci; 1987 Jul; 41(1):79-87. PubMed ID: 3037218
[TBL] [Abstract][Full Text] [Related]
5. Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors.
Krowicki ZK; Moerschbaecher JM; Winsauer PJ; Digavalli SV; Hornby PJ
Eur J Pharmacol; 1999 Apr; 371(2-3):187-96. PubMed ID: 10357256
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats.
Lake KD; Martin BR; Kunos G; Varga K
Hypertension; 1997 May; 29(5):1204-10. PubMed ID: 9149688
[TBL] [Abstract][Full Text] [Related]
7. Effects of delta-9-tetrahydrocannabinol on the cardiovascular system, and pressor and behavioral responses to brain stimulation in rats.
Kawasaki H; Watanabe S; Oishi R; Ueki S
Jpn J Pharmacol; 1980 Aug; 30(4):493-502. PubMed ID: 6259394
[TBL] [Abstract][Full Text] [Related]
8. Antinociception and cardiovascular responses produced by intravenous morphine: the role of vagal afferents.
Randich A; Thurston CL; Ludwig PS; Timmerman MR; Gebhart GF
Brain Res; 1991 Mar; 543(2):256-70. PubMed ID: 2059834
[TBL] [Abstract][Full Text] [Related]
9. [Paticipation of cannabinoid receptors in the regulation of cardiac rhythm and cardiac contractility].
Maslov LN; Ermakov SIu; Lasukova OV; Barzakh EI; Krylatov AV; Crawford D; Serebrov VIu
Ross Fiziol Zh Im I M Sechenova; 2006 Apr; 92(4):429-39. PubMed ID: 16813149
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats.
Martín-Calderón JL; Muñoz RM; Villanúa MA; del Arco I; Moreno JL; de Fonseca FR; Navarro M
Eur J Pharmacol; 1998 Feb; 344(1):77-86. PubMed ID: 9580419
[TBL] [Abstract][Full Text] [Related]
11. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
Rodríguez de Fonseca F; Rubio P; Menzaghi F; Merlo-Pich E; Rivier J; Koob GF; Navarro M
J Pharmacol Exp Ther; 1996 Jan; 276(1):56-64. PubMed ID: 8558457
[TBL] [Abstract][Full Text] [Related]
12. The triple effect induced by delta 9-tetrahydrocannabinol on the rat blood pressure.
Siqueira SW; Lapa AJ; Ribeiro do Valle J
Eur J Pharmacol; 1979 Oct; 58(4):351-7. PubMed ID: 510372
[TBL] [Abstract][Full Text] [Related]
13. Tolerance to the cardiovascular effects of delta9-tetrahydrocannabinol in the rat.
Adams MD; Chait LD; Earnhardt JT
Br J Pharmacol; 1976 Jan; 56(1):43-8. PubMed ID: 1252665
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of the intraocular pressure (IOP) lowering effect of systemic dexanabinol (HU-211), a non-psychotropic cannabinoid.
Beilin M; Neumann R; Belkin M; Green K; Bar-Ilan A
J Ocul Pharmacol Ther; 2000 Jun; 16(3):217-30. PubMed ID: 10872919
[TBL] [Abstract][Full Text] [Related]
15. The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys.
Fredericks AB; Benowitz NL; Savanapridi CY
J Pharmacol Exp Ther; 1981 Feb; 216(2):247-53. PubMed ID: 6257883
[TBL] [Abstract][Full Text] [Related]
16. The in vitro and in vivo cardiovascular effects of Delta9-tetrahydrocannabinol in rats made hypertensive by chronic inhibition of nitric-oxide synthase.
O'Sullivan SE; Randall MD; Gardiner SM
J Pharmacol Exp Ther; 2007 May; 321(2):663-72. PubMed ID: 17284670
[TBL] [Abstract][Full Text] [Related]
17. Maternal exposure to the synthetic cannabinoid HU-210: effects on the endocrine and immune systems of the adult male offspring.
del Arco I; Muñoz R; Rodríguez De Fonseca F; Escudero L; Martín-Calderón JL; Navarro M; Villanúa MA
Neuroimmunomodulation; 2000; 7(1):16-26. PubMed ID: 10601815
[TBL] [Abstract][Full Text] [Related]
18. Effects of chronic administration of delta 9-tetrahydrocannabinol on the cardiovascular system, and pressor and behavioral responses to brain stimulation in freely moving rats.
Kawasaki H; Watanabe S; Ueki S
Eur J Pharmacol; 1980 Jul; 65(1):63-9. PubMed ID: 6249621
[TBL] [Abstract][Full Text] [Related]
19. Prolonged delta-9-tetrahydrocannabinol ingestion. Effects of sympathomimetic amines and autonomic blockades.
Benowitz NL; Jones RT
Clin Pharmacol Ther; 1977 Mar; 21(3):336-42. PubMed ID: 837652
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of eugenol, a phenolic compound present in many plant essential oils, in normotensive rats.
Lahlou S; Interaminense LF; Magalhães PJ; Leal-Cardoso JH; Duarte GP
J Cardiovasc Pharmacol; 2004 Feb; 43(2):250-7. PubMed ID: 14716213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
